An early-stage investment and development firm based in the United States operates under an evergreen investment structure. The firm manages substantial long-term capital and maintains flexibility in both investment size and transaction structure. Initial investments typically range from approximately $1M to $10M, with additional reserves available for continued support of successful portfolio companies.
The firm focuses on medical devices and research tools. Within medical devices, the firm prefers technologies pursuing higher-barrier regulatory pathways, including PMA approvals. Within research tools, the firm invests in technologies that enable or enhance the discovery and manufacturing of therapeutics and diagnostics, particularly those with meaningful commercial scalability and strong recurring revenue potential.
From a company and management team perspective, the firm seeks to invest in small, early-stage companies led by lean but highly capable management and execution teams. The firm primarily focuses on opportunities in the United States while remaining open to select opportunities in Europe.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment